Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2010

View Archived Issues

DEN1-80E and DEN-80E dengue virus vaccines show promise

MenACWY-CRM produces robust immunogenicity in infants

Exenatide is beneficial in patients with nonalcoholic steatohepatitis

Astex's AT-9283 enters phase II trial in multiple myeloma

Novartis discontinues clinical program for anticancer candidate ASA-404

Bionovo receives FDA approval for clinical development plan for Menerba

Eisai reports developments of first half fiscal year 2010

NCX-429 has anti-inflammatory activity in several preclinical models

Cell surface glycoprotein MUC18 is a marker for malignant pleural mesothelioma

Repros Therapeutics reports on type B meeting with FDA regarding Androxal

Clavis Pharma and Clovis Oncology sign additional agreement for CP-4126

FDA approves Egrifta for lipodystrophy in HIV-infected patients

AstraZeneca describes new GSK-3 inhibitors

First patient treated in phase IIb AP-214 trial

Hygeia Therapeutics completes preclinical studies of HYG-102

Choongwae Pharma claims new reverse-turn mimetics for treatment of AML

Novel mTOR inhibitors presented by Merck & Co.

Banyu Pharma claims new bile acid GPBA receptor agonists

Canadian scientists identify new antimitotic agents

FDA clears PolyMedix's IND application for PMX-30063

CytRx begins pharmacokinetic bafetinib trial in patients with brain cancer

EMA committee recommends orphan drug status for ThermoDox in primary liver cancer

Centocor Ortho Biotech submits sBLA to FDA to expand Simponi label

Aeras Global TB Vaccine Foundation receives additional grant from Dutch government

Sangamo BioSciences receives U.S. government grants for four programs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...